Efficacy and safety of non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation: A meta-analysis

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Santarpia, Giuseppe ^a   De Rosa, Salvatore ^a   Polimeni, Alberto ^a   Giampà, Salvatore ^a   Micieli, Mariella ^a   Curcio, Antonio ^a   Indolfi, Ciro ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DABIGATRAN; LOW MOLECULAR WEIGHT HEPARIN; NONVITAMIN K ANTAGONIST ORAL ANTICOAGULANT AGENT; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; GASTROINTESTINAL HEMORRHAGE; HUMAN; INCIDENCE; META ANALYSIS; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SILENT CEREBRAL ISCHEMIA; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; ANTAGONISTS AND INHIBITORS; BLEEDING; CHEMICALLY INDUCED; PROCEDURES;

SUBGROUP A;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; HEMORRHAGE; HUMANS; INCIDENCE; STROKE; THROMBOEMBOLISM; VITAMIN K;

EID: 84929493146     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126512     Document Type: Article

References (46)

1. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001; 86: 516-521. PMID: 11602543
2. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics - 2009 update: A report from the AHA Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009; 119: 480-486. doi: 10.1161/CIRCULATIONAHA.108.191259 PMID: 19171871
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine. 2007; 146: 857-867. PMID: 17577005
4. Samsa GP, Matchar DB, Goldstein LB, Bonito AJ, Lux LJ, Witter DM, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000; 160: 967-973. PMID: 10761962
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151. doi: 10.1056/NEJMoa0905561 PMID: 19717844
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891. doi: 10.1056/NEJMoa1009638 PMID: 21830957
7. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992. doi: 10.1056/NEJMoa1107039 PMID: 21870978
8. Camm JA, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012; 33: 2719-2747. doi: 10.1093/eurheartj/ehs253 PMID: 22922413
9. De Rosa S, Caiazzo G, Torella D, Indolfi C. Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: A meta-analysis of clinical trials. Int J Cardiol. 2012; 168: 1298-1305. doi: 10.1016/j.ijcard.2012.12.003 PMID: 23273690
10. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement. PLoS Med. 2009; 6:e1000097. doi: 10.1371/journal.pmed.1000097 PMID: 19621072
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188. PMID: 3802833
12. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719-748. PMID: 13655060
13. De Rosa S, Caiazzo G, Torella D, Indolfi C. Letter to the editor: Intracoronary versus intravenous abciximab bolus administration. J Am Coll Cardiol. 2014; 63: 1340-1341. doi: 10.1016/j.jacc.2013.08.1662 PMID: 24412448
14. De Rosa S, Torella D, Caiazzo G, Giampà S, Indolfi C. Left radial access for percutaneous coronary procedures: from neglected to performer? A meta-analysis of 14 studies including 7,603 procedures. Int J Cardiol. 2014; 171: 66-72. doi: 10.1016/j.ijcard.2013.11.046 PMID: 24331866
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ. 1997; 315: 629-634. PMID: 9310563
16. Maddox W, Kay GN, Yamada T, Osorio J, Doppalapudi H, Plumb VJ, et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2013; 24: 861-865. doi: 10.1111/jce.12143 PMID: 23577951
17. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban. Europace. 2014; 16: 1443-1449. doi: 10.1093/europace/euu196 PMID: 25115168
18. Ichiki H, Oketani N, Ishida S, Iriki Y, Okui H, Maenosono R, et al. The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran. PACE. 2013; 36: 1328-1335. doi: 10.1111/pace.12195 PMID: 23952291
19. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with Rivaroxaban and Warfarin in the ROCKET AF Trial. J Am Coll Cardiol. 2013; 61: 1998-2006. doi: 10.1016/j.jacc.2013.02.025 PMID: 23500298
20. Kaseno K, Naito S, Nakamura K, Sakamoto T, Sasaki T, Tsukada N, et al. Efficacy and safety of peri-procedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J. 2012; 76: 2337-2342. PMID: 22785434
21. Snipelisky D, Kauffman C, Prussak K, Johns G, Venkatachalam K, Kusumoto F. Comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol. 2012; 35: 29-33. doi: 10.1007/s10840-012-9708-z PMID: 22869389
22. Konduru SV, Cheema AA, Jones P, Li Y, Ramza B, Wimmer AP. Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin. J Interv Card Electrophysiol. 2012; 35: 277-284. doi: 10.1007/s10840-012-9719-9 PMID: 23015216
23. Kaiser DW, Streur MM, Nagarakanti R, Whalen SP, Ellis CR. Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. J Interv Card Electrophysiol. 2013; 37: 241-247. doi: 10.1007/s10840-013-9793-7 PMID: 23625091
24. Haines DE, Mead-Salley M, Salazar M, Marchlinski FE, Zado E, Calkins H, et al. Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. J Interv Card Electrophysiol. 2013; 37: 233-239. doi: 10.1007/s10840-013-9800-z PMID: 23740224
25. Bernard M, Brabham W, Netzler P, Rowley C, Gold M, Leman R, et al. Comparison of atrial fibrillation ablation bleeding and thrombotic complications with dabigatran, rivaroxaban and warfarin. J Am Coll Cardiol. 2013; 61(Suppl):E276. PMID: 24236310
26. Kim JS, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2013; 10: 483-489. doi: 10.1016/j.hrthm.2012.12.011 PMID: 23237911
27. Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M, et al. Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. Clin Drug Investig. 2013; 33: 409-418. doi: 10.1007/s40261-013-0081-1 PMID: 23572324
28. Mendoza I, Helguera M, Baez-Escudero J, Reina J, Pinski SL. Atrial fibrillation ablation on uninterrupted anticoagulation with dabigatran versus warfarin. Heart Rhythm. 2012; 9(5Suppl 1):S270-1.
29. Rowley CP, Bradford NS, Bernard ML, Sidney DS, Brabham WW, Netzler PC, et al. Complications of atrial fibrillation ablation in patients anticoagulated with dabigatran compared to warfarin. Heart Rhythm. 2012; 9 (5Suppl 1):S201.
30. Pavaci H, Reents T, Ammar S, Fichtner S, Schoen P, Kathan S, et al. Safety and efficacy of dabigatran in patients undergoing left atrial ablation procedures: a case-matched analysis. Eur Heart J. 2012; 33: 60-61. doi: 10.1093/eurheartj/ehr257 PMID: 21804108
31. Ellis CR, Streur MM, Nagarakanti R. Safety and efficacy of dabigatran versus warfarin in patients undergoing left atrial catheter ablation. Heart Rhythm. 2012; 9: S421.
32. Stepanyan G, Badhwar N, Lee RJ, Marcus GM, Lee BK, Tseng ZH, et al. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. J Interv Card Electrophysiol. 2014; 40: 33-38. doi: 10.1007/s10840-014-9888-9 PMID: 24643666
33. Arshad A, Johnson CK, Mittal S, Buch E, Hamam I, Tran T, et al. Comparative Safety of Periablation Anticoagulation Strategies for Atrial Fibrillation: Data from a Large Multicenter Study. Pacing Clin Electrophysiol. 2014; 37: 665-673. doi: 10.1111/pace.12401 PMID: 24797604
34. Dillier R, Ammar S, Hessling G, Kaess B, Pavaci H, Buiatti A, et al. Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures. Circ Arrhythm Electrophysiol. 2014; 7: 576-582. doi: 10.1161/CIRCEP.114.001586 PMID: 24970293
35. Kaess BM, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V, et al. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol. 2015; 115: 47-51. doi: 10.1016/j.amjcard.2014.10.005 PMID: 25456870
36. Nin T, Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasatur M, et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. PACE. 2013; 36: 172-179. doi: 10.1111/pace.12036 PMID: 23121681
37. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation. J Am Coll Cardiol. 2012; 59: 1168-1174. doi: 10.1016/j.jacc.2011.12.014 PMID: 22305113
38. Imamura K, Yoshida A, Takei A, Fukuzawa K, Kiuchi K, Takami K, et al. Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. J Interv Card Electrophysiol. 2013; 37: 223-231. doi: 10.1007/s10840-013-9801-y PMID: 23585240
39. Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M, et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2013; 6: 460-466. doi: 10.1161/CIRCEP.113.000320 PMID: 23553523
40. Providencia R, Marijon E, Albenque J, Combes S, Combes N, Jourda F, et al. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace. 2014; 16: 1137-1144. doi: 10.1093/europace/euu007 PMID: 24550347
41. Sardar P, Nairooz R, Chatterjee S, Wetterslev J, Ghosh J, Aronow WS. Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. Am J Cardiol. 2014; 113: 1173-1177. doi: 10.1016/j.amjcard.2013.12.027 PMID: 24513472
42. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of Coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) Randomized Trial. Circulation. 2014; 129: 2638-2644. doi: 10.1161/CIRCULATIONAHA.113.006426 PMID: 24744272
43. Shurrab M, Morillo CA, Schulman S, Kansal N, Danon A, Newman D, et al. Safety and Efficacy of Dabigatran Compared With Warfarin for Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-analysis. Can J Cardiol. 2013; 29: 1203-1210. doi: 10.1016/j.cjca.2013.07.005 PMID: 23993352
44. Providência R, Albenque JP, Combes S, Bouzeman A, Casteigt B, Combes N, et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart. 2014; 100: 324-335. doi: 10.1136/heartjnl-2013-304386 PMID: 23878175
45. Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace. 2013; 15: 1407-1411. doi: 10.1093/europace/eut241 PMID: 23954917
46. Karasoy D, Gislason GH, Hansen J, Johannessen A, Køber L, Hvidtfeldt M, et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark. Eur Heart J. 2015; 36: 307-315. doi: 10.1093/eurheartj/ehu421 PMID: 25368205